These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19650867)

  • 1. Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice.
    Renninger ML; Seymour RE; Whiteley LO; Sundberg JP; Hogenesch H
    Exp Dermatol; 2010 Mar; 19(3):252-8. PubMed ID: 19650867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling.
    Potter CS; Wang Z; Silva KA; Kennedy VE; Stearns TM; Burzenski L; Shultz LD; Hogenesch H; Sundberg JP
    PLoS One; 2014; 9(1):e85666. PubMed ID: 24465642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.
    Liang Y; Seymour RE; Sundberg JP
    J Invest Dermatol; 2011 Jan; 131(1):141-9. PubMed ID: 20811394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrin beta 1 inhibition alleviates the chronic hyperproliferative dermatitis phenotype of SHARPIN-deficient mice.
    Peuhu E; Salomaa SI; De Franceschi N; Potter CS; Sundberg JP; Pouwels J
    PLoS One; 2017; 12(10):e0186628. PubMed ID: 29040328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenesis of chronic eosinophilic esophagitis in SHARPIN-deficient mice.
    Chien SJ; Silva KA; Kennedy VE; HogenEsch H; Sundberg JP
    Exp Mol Pathol; 2015 Dec; 99(3):460-7. PubMed ID: 26321245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct role of IL-1β in instigating disease in Sharpin
    Gurung P; Sharma BR; Kanneganti TD
    Sci Rep; 2016 Nov; 6():36634. PubMed ID: 27892465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice.
    Renninger ML; Seymour R; Lillard JW; Sundberg JP; HogenEsch H
    Exp Dermatol; 2005 Dec; 14(12):906-13. PubMed ID: 16274458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate immune adaptor MyD88 deficiency prevents skin inflammation in SHARPIN-deficient mice.
    Sharma BR; Karki R; Lee E; Zhu Q; Gurung P; Kanneganti TD
    Cell Death Differ; 2019 Mar; 26(4):741-750. PubMed ID: 30038386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHARPIN regulates mitochondria-dependent apoptosis in keratinocytes.
    Liang Y; Sundberg JP
    J Dermatol Sci; 2011 Sep; 63(3):148-53. PubMed ID: 21620685
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Siitonen R; Peuhu E; Autio A; Liljenbäck H; Mattila E; Metsälä O; Käkelä M; Saanijoki T; Dijkgraaf I; Jalkanen S; Ivaska J; Roivainen A
    J Nucl Med; 2019 Oct; 60(10):1380-1387. PubMed ID: 30850498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm).
    Gijbels MJ; Zurcher C; Kraal G; Elliott GR; HogenEsch H; Schijff G; Savelkoul HF; Bruijnzeel PL
    Am J Pathol; 1996 Mar; 148(3):941-50. PubMed ID: 8774148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12.
    HogenEsch H; Torregrosa SE; Boggess D; Sundberg BA; Carroll J; Sundberg JP
    Eur J Immunol; 2001 Mar; 31(3):734-42. PubMed ID: 11241277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis.
    Seymour RE; Hasham MG; Cox GA; Shultz LD; Hogenesch H; Roopenian DC; Sundberg JP
    Genes Immun; 2007 Jul; 8(5):416-21. PubMed ID: 17538631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of chitinase-like proteins in the skin of chronic proliferative dermatitis (cpdm/cpdm) mice.
    HogenEsch H; Dunham A; Seymour R; Renninger M; Sundberg JP
    Exp Dermatol; 2006 Oct; 15(10):808-14. PubMed ID: 16984263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
    Kuruvilla M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiogenesis in the skin of SHARPIN-deficient mice with chronic proliferative dermatitis.
    HogenEsch H; Sola M; Stearns TM; Silva KA; Kennedy VE; Sundberg JP
    Exp Mol Pathol; 2016 Dec; 101(3):303-307. PubMed ID: 27794420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Airway hyperresponsiveness: first eosinophils and then neuropeptides.
    Kraneveld AD; Folkerts G; Van Oosterhout AJ; Nijkamp FP
    Int J Immunopharmacol; 1997; 19(9-10):517-27. PubMed ID: 9637348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm).
    Gijbels MJ; Elliott GR; HogenEsch H; Zurcher C; van den Hoven A; Bruijnzeel PL
    Exp Dermatol; 2000 Oct; 9(5):351-8. PubMed ID: 11016856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss-of-function of SHARPIN causes an osteopenic phenotype in mice.
    Xia T; Liang Y; Ma J; Li M; Gong M; Yu X
    Endocrine; 2011 Apr; 39(2):104-12. PubMed ID: 21069580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell death.
    Ang RL; Chan M; Legarda D; Sundberg JP; Sun SC; Gillespie VL; Chun N; Heeger PS; Xiong H; Lira SA; Ting AT
    Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34887354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.